There are diverging opinions on whether comparative efficacy trials add much of value to the evidence for biosimilar approval in the United States.
There are diverging opinions on whether comparative efficacy trials add much of value to the evidence for biosimilar approval in the United States.
Which of the following best describes your opinion?
Check out the results from our last poll: